GO
Loading...

Novartis AG

More

  • *Novartis commits $225 mln upfront to private biotech firm. *Novartis also picks top scientist to lead immuno-oncology. March 30- Swiss drugmaker Novartis is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech worth up to $750 million.

  • Britain to offer all infants meningitis B vaccine Sunday, 29 Mar 2015 | 12:08 PM ET

    LONDON— Britain says it will become the first country to offer all babies a vaccine for potentially fatal meningitis B after it reached a price deal with GlaxoSmithKline PLC. The drug was owned by Novartis, which recently sold most of its vaccines business to GlaxoSmithKline. Health Secretary Jeremy Hunt said Sunday he was "very proud that we will be the first...

  • Science, patients driving rare disease drug research surge Wednesday, 25 Mar 2015 | 10:38 AM ET

    TRENTON, N.J.— The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era of innovative therapies and big profits. The investments come as researchers harness recent scientific advances, including the mapping of...

  • JERUSALEM, March 25- Israeli biopharmaceutical company BioLineRX Ltd said on Wednesday an early stage trial for a drug that uses stem cells to treat leukaemia and other blood cancers met all safety and efficacy goals. Current stem cell treatments require four or five days of injections of material from a donor to get into the bloodstream, but BioLineRX said its...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • NEW YORK, March 22- As the dollar surged in the last 12 months, David Marcus, head of the Evermore Global Value fund, steadily increased his stake in Europe. Demand for a way to hedge currency exposure while investing in Europe helped the WisdomTree Europe Hedged Equity Fund bring in $5.3 billion in new assets over the first two months of the year, the most of any equity...

  • NEW YORK, March 19- A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The judge denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat drug.

  • LONDON, March 12- Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. For many years the vaccines industry has been dominated by five big companies, but that has shrunk to four with GlaxoSmithKline's purchase of Novartis' business.

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • *Zarxio from Novartis generics unit Sandoz approved by FDA. *Copy of Amgen's white cell-boosting medicine Neupogen. The move had been expected after Zarxio, which is made by Novartis' generics unit Sandoz, won unanimous backing from an FDA panel in January.

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • March 5- AbbVie Inc is to buy Pharmacyclics Inc for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Deutsche Bank analyst...

  • *AbbVie to pay $261.25 per share in cash and stock. The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago- based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical...

  • March 4- Johnson& Johnson is close to buying cancer drug maker Pharmacyclics Inc in the coming days, the Financial Times reported, citing sources. A bid from J&J is expected to value Pharmacyclics near its $17.5 billion market value or at a premium, FT said on Wednesday, citing people familiar with the matter. Bloomberg reported last month, citing sources, that...

  • March 4- Vanda Pharmaceuticals Inc said its experimental atopic dermatitis drug failed a mid-stage study to treat chronic itching. It affects between 9 and 30 percent of the U.S. population, according to the National Institutes of Health. The company regained the U.S. and Canada rights for its schizophrenia drug Fanapt from Novartis AG late last year.

  • *Sonova buy Germany's Hansaton Akustik. ZURICH, March 2- Sonova, the world's largest maker of hearing aids, will shift jobs out of Switzerland and freeze pay for Swiss staff as it cuts costs to cope with a surge in the value of the franc. Sonova said on Monday that 100 jobs would be lost in Switzerland, with some manufacturing roles shifted to China and client services...

  • LONDON, March 2- GlaxoSmithKline and Novartis said on Monday they had completed a series of asset swaps worth more than $20 billion that will reshape both drugmakers. GSK is forming a consumer health joint venture with Novartis, while at the same time buying the Swiss company's vaccines business and divesting its cancer drugs portfolio to Novartis.

  • Feb 25- Cancer drug maker Pharmacyclics Inc is exploring a sale and has attracted interest from Johnson& Johnson and Novartis AG, Bloomberg reported. Pharmacyclics could fetch $17 billion- $18 billion from a possible sale, Bloomberg said on Wednesday, citing people familiar with the matter. A Pharmacyclics official said the company does not comment on rumors or...